Outlook Therapeutics Clears Nasdaq Hurdle but Faces $39M Debt and FDA Deadline

Outlook Therapeutics has escaped the threat of expulsion from the Nasdaq Capital Market, but the relief is tempered by a precarious balance sheet and a looming regulatory verdict. The biopharma company’s shares slipped roughly 5% to $1.60 on the day the delisting risk was officially removed, reflecting investor caution rather than celebration. The stock still trades near $1.69, giving the company a market capitalisation of around $138 million — a valuation that hinges entirely on a single experimental drug.

The Nasdaq compliance issue stemmed from a prolonged period during which the share price languished below the required $1.00 minimum. That changed in late June, when the stock closed above that threshold for ten consecutive trading days — enough to satisfy the exchange’s listing rules. The formal closure of the delisting proceeding removes a technical overhang, but the underlying financial challenges remain stark.

End of March, Outlook Therapeutics held just $7.7 million in cash against short-term liabilities of nearly $39 million. The quarterly net loss narrowed sharply to $4.5 million year-on-year, yet the cash burn rate leaves little room for error. Without a swift infusion of revenue or a regulatory green light, the company’s runway looks tight.

Should investors sell immediately? Or is it worth buying Outlook Therapeutics?

To shore up liquidity, management turned to a direct share placement in May, raising $5 million from major shareholder GMS Ventures. The investor received approximately 8.5 million new shares at $0.5855 apiece — a deep discount to the current market price. At the same time, Outlook adjusted the exercise price of existing warrants held by the same investor, lowering the strike for roughly 15.5 million securities to that same level. The moves dilute existing shareholders, even as they buy the company breathing room.

The real prize remains Lytenava, a treatment for wet age-related macular degeneration. In Europe and the UK, the drug has already secured marketing authorisation, and commercial launches have begun in Germany, Austria and Britain. In the US, the FDA accepted a newly submitted biologics license application in June and granted it an accelerated review. A decision is expected imminently, and without it, the company’s slender cash reserves could become an existential threat.

The Nasdaq reprieve buys management valuable time, but the stock’s trajectory now depends on two binary events: the FDA’s ruling and the first sales figures from Europe. With a 143% year-to-date gain already in the books, any disappointment could trigger a sharp reversal. Until then, Outlook Therapeutics remains a high-stakes speculative play.